CompletedPhase 2NCT05717062
Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)
Studying Snakebite envenomation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ophirex, Inc.
- Principal Investigator
- Timothy Platts-Mills, MD, MSc, M.DOphirex, Inc.
- Intervention
- Varespladib intravenous form(drug)
- Enrollment
- 140 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2025
Study locations (10)
- Banner University Medical Center - Phoenix, Phoenix, Arizona, United States
- Arizona Poison & Drug Information Center, Tucson, Arizona, United States
- Desert Regional Medical Center, Palm Springs, California, United States
- Antelope Valley Medical Center, Rosamond, California, United States
- UF Health Shands Hospital, Gainesville, Florida, United States
- University of South Florida/Tampa General Hospital, Tampa, Florida, United States
- Emergency Medicine, University of Kentucky, Lexington, Kentucky, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Texas Tech University Health Sciences Center El Paso, El Paso, Texas, United States
- UT Health San Antonio, San Antonio, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05717062 on ClinicalTrials.govOther trials for Snakebite envenomation
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07261982Analysis of the Efficacy of Pressure Pad vs Pressure Bandage Immobilisation for Snake Bite First Aid in Healthy Volunteers.Townsville University Hospital
- RECRUITINGNCT06304714Effects of Bothrops Spp. Snake Envenomation on Willebrand Factor Activity in Martinique and French GuianaUniversity Hospital Center of Martinique